The paediatric segment represents around two-thirds of the total market. "Given the vast unmet public health needs in invasive pneumococcal disease (IPD), we’re delighted to expand this collaboration ...
This vaccine candidate is the first-ever PCV containing more than 20 serotypes to enter a phase 3 clinical study in infants and toddlers. Thomas Triomphe Executive Vice President, Vaccines, Sanofi ...